vs
Side-by-side financial comparison of Royalty Pharma plc (RPRX) and UPBOUND GROUP, INC. (UPBD). Click either name above to swap in a different company.
UPBOUND GROUP, INC. is the larger business by last-quarter revenue ($1.2B vs $622.0M, roughly 1.9× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 1.7%, a 32.8% gap on every dollar of revenue. On growth, UPBOUND GROUP, INC. posted the faster year-over-year revenue change (10.9% vs 4.8%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs 4.5%).
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
Upbound Group, Inc. is a leading US provider of flexible lease-to-own solutions for consumer goods. It offers furniture, consumer electronics, home appliances, and accessories, catering to customers seeking accessible payment alternatives to traditional retail financing.
RPRX vs UPBD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $622.0M | $1.2B |
| Net Profit | $214.2M | $19.7M |
| Gross Margin | — | 49.0% |
| Operating Margin | 62.4% | 4.8% |
| Net Margin | 34.4% | 1.7% |
| Revenue YoY | 4.8% | 10.9% |
| Net Profit YoY | 2.9% | -36.3% |
| EPS (diluted) | $0.49 | $0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $622.0M | $1.2B | ||
| Q3 25 | $609.3M | $1.2B | ||
| Q2 25 | $578.7M | $1.2B | ||
| Q1 25 | $568.2M | $1.2B | ||
| Q4 24 | $593.6M | $1.1B | ||
| Q3 24 | $564.7M | $1.1B | ||
| Q2 24 | $537.3M | $1.1B | ||
| Q1 24 | $568.0M | $1.1B |
| Q4 25 | $214.2M | $19.7M | ||
| Q3 25 | $288.2M | $13.2M | ||
| Q2 25 | $30.2M | $15.5M | ||
| Q1 25 | $238.3M | $24.8M | ||
| Q4 24 | $208.2M | $31.0M | ||
| Q3 24 | $544.0M | $30.9M | ||
| Q2 24 | $102.0M | $33.9M | ||
| Q1 24 | $4.8M | $27.7M |
| Q4 25 | — | 49.0% | ||
| Q3 25 | — | 48.3% | ||
| Q2 25 | — | 49.4% | ||
| Q1 25 | — | 46.8% | ||
| Q4 24 | — | 47.1% | ||
| Q3 24 | — | 47.8% | ||
| Q2 24 | — | 49.4% | ||
| Q1 24 | — | 48.3% |
| Q4 25 | 62.4% | 4.8% | ||
| Q3 25 | 70.1% | 4.5% | ||
| Q2 25 | 36.3% | 4.4% | ||
| Q1 25 | 94.0% | 5.3% | ||
| Q4 24 | 60.9% | 7.3% | ||
| Q3 24 | — | 6.6% | ||
| Q2 24 | 50.2% | 7.5% | ||
| Q1 24 | -13.0% | 5.6% |
| Q4 25 | 34.4% | 1.7% | ||
| Q3 25 | 47.3% | 1.1% | ||
| Q2 25 | 5.2% | 1.3% | ||
| Q1 25 | 41.9% | 2.1% | ||
| Q4 24 | 35.1% | 2.9% | ||
| Q3 24 | 96.3% | 2.9% | ||
| Q2 24 | 19.0% | 3.2% | ||
| Q1 24 | 0.8% | 2.5% |
| Q4 25 | $0.49 | $0.35 | ||
| Q3 25 | $0.67 | $0.22 | ||
| Q2 25 | $0.07 | $0.26 | ||
| Q1 25 | $0.55 | $0.42 | ||
| Q4 24 | $0.46 | $0.55 | ||
| Q3 24 | $1.21 | $0.55 | ||
| Q2 24 | $0.23 | $0.61 | ||
| Q1 24 | $0.01 | $0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $618.7M | $120.5M |
| Total DebtLower is stronger | $9.0B | — |
| Stockholders' EquityBook value | $9.7B | $695.7M |
| Total Assets | $19.6B | $3.3B |
| Debt / EquityLower = less leverage | 0.92× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $618.7M | $120.5M | ||
| Q3 25 | $938.9M | $107.0M | ||
| Q2 25 | $631.9M | $106.8M | ||
| Q1 25 | $1.1B | $107.3M | ||
| Q4 24 | $929.0M | $60.9M | ||
| Q3 24 | $950.1M | $85.1M | ||
| Q2 24 | $1.8B | $82.5M | ||
| Q1 24 | $843.0M | $84.8M |
| Q4 25 | $9.0B | — | ||
| Q3 25 | $8.9B | — | ||
| Q2 25 | $8.0B | — | ||
| Q1 25 | $7.6B | — | ||
| Q4 24 | $7.6B | — | ||
| Q3 24 | $7.6B | — | ||
| Q2 24 | $7.6B | — | ||
| Q1 24 | $6.1B | — |
| Q4 25 | $9.7B | $695.7M | ||
| Q3 25 | $9.6B | $687.3M | ||
| Q2 25 | $9.5B | $685.5M | ||
| Q1 25 | $9.8B | $679.2M | ||
| Q4 24 | $10.3B | $629.0M | ||
| Q3 24 | $10.3B | $611.8M | ||
| Q2 24 | $9.8B | $596.3M | ||
| Q1 24 | $9.9B | $578.3M |
| Q4 25 | $19.6B | $3.3B | ||
| Q3 25 | $19.3B | $3.2B | ||
| Q2 25 | $18.3B | $3.1B | ||
| Q1 25 | $17.6B | $3.0B | ||
| Q4 24 | $18.2B | $2.6B | ||
| Q3 24 | $18.0B | $2.6B | ||
| Q2 24 | $17.7B | $2.6B | ||
| Q1 24 | $16.1B | $2.6B |
| Q4 25 | 0.92× | — | ||
| Q3 25 | 0.93× | — | ||
| Q2 25 | 0.84× | — | ||
| Q1 25 | 0.78× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 0.74× | — | ||
| Q2 24 | 0.78× | — | ||
| Q1 24 | 0.62× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $827.1M | $41.6M |
| Free Cash FlowOCF − Capex | — | $24.0M |
| FCF MarginFCF / Revenue | — | 2.0% |
| Capex IntensityCapex / Revenue | — | 1.5% |
| Cash ConversionOCF / Net Profit | 3.86× | 2.11× |
| TTM Free Cash FlowTrailing 4 quarters | — | $238.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $827.1M | $41.6M | ||
| Q3 25 | $702.6M | $118.4M | ||
| Q2 25 | $364.0M | $7.8M | ||
| Q1 25 | $596.1M | $137.7M | ||
| Q4 24 | $742.5M | $-61.9M | ||
| Q3 24 | $703.6M | $106.2M | ||
| Q2 24 | $658.2M | $15.0M | ||
| Q1 24 | $664.6M | $45.4M |
| Q4 25 | — | $24.0M | ||
| Q3 25 | — | $97.9M | ||
| Q2 25 | — | $-10.4M | ||
| Q1 25 | — | $127.2M | ||
| Q4 24 | — | $-74.0M | ||
| Q3 24 | — | $88.3M | ||
| Q2 24 | — | $613.0K | ||
| Q1 24 | — | $33.6M |
| Q4 25 | — | 2.0% | ||
| Q3 25 | — | 8.4% | ||
| Q2 25 | — | -0.9% | ||
| Q1 25 | — | 10.8% | ||
| Q4 24 | — | -6.9% | ||
| Q3 24 | — | 8.3% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 3.1% |
| Q4 25 | — | 1.5% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | — | 1.6% | ||
| Q1 25 | — | 0.9% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | — | 1.7% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | 1.1% |
| Q4 25 | 3.86× | 2.11× | ||
| Q3 25 | 2.44× | 8.96× | ||
| Q2 25 | 12.06× | 0.50× | ||
| Q1 25 | 2.50× | 5.56× | ||
| Q4 24 | 3.57× | -2.00× | ||
| Q3 24 | 1.29× | 3.44× | ||
| Q2 24 | 6.45× | 0.44× | ||
| Q1 24 | 139.10× | 1.64× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
UPBD
Segment breakdown not available.
